After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
|Articles|May 8, 2021
CURE Honors World Ovarian Cancer Day
Author(s)Jessica Skarzynski
Today is World Ovarian Cancer Day, and in honor of this day that was created in 2013 to raise awareness about the disease, CURE® is rounding up the latest news and updates in this cancer space.
Advertisement
In honor of World Ovarian Cancer Day, which was created in 2013 to raise awareness about the disease, CURE® rounded up the latest news and updates in this cancer space:
- Despite on-treatment clinical progression, patients
treated with Avastin (bevacizumab) and standard chemotherapy had a median progression-free survival of 11.8 months compared with 8.8 months in those treated with standard chemotherapy alone.
- In this episode of the “CURE® Talks Cancer” podcast, we spoke with an
ovarian cancer survivor and teacher about how she maintained her sense of humor through treatment and why it’s important to remain connected to friends and family, especially during the darkest moments.
- Following
chemotherapy with secondary cytoreduction for patients with platinum-sensitive relapsed ovarian cancer contributed to longer progression-free survival compared with chemotherapy alone, according to study results published in The Lancet Oncology.
Maintenance therapy with a PARP inhibitor demonstrated benefits including progression-free survival for those with high-grade, recurrent, platinum-sensitive ovarian cancer, according to data published in Cancer.
- Fertility treatments led to an ovarian cancer diagnosis but also opened the door to adoption and a new view on life for
Elizabeth Johnston , who shared her story with us in our latest Women’s Cancers Special Issue.
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Sue Weldon, a 22-year breast cancer survivor and Unite for HER founder, explains how integrative therapies helped her heal after chemotherapy.
Living with metastatic breast cancer can make Pinktober feel complicated. One patient reflects on awareness, research, loss and remembering the people behind the pink.
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Advertisement
Advertisement
Trending on CURE
1
Radiation Oncologist Answers Top Questions About Radiation Therapy
2
5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
3
Former Hospital Executive on Risks Patients With Cancer Face After Discharge
4
What Patients Should Know About Nipple-Sparing Mastectomy for Breast Cancer
5